Teva Biosimilars - Press Kit and Media Assets
Access materials about Teva's Biosimilar medicines, including press releases, reports and media resources.
Teva Biosimilar Medicines
Teva is significantly accelerating the growth of its biosimilars business to broaden access to biologic medicines, support more sustainable healthcare systems and strengthen its position as a global biopharmaceutical company. We have a 125-year legacy of delivering affordable medicine and are committed to delivering accessible biosimilars globally.
Explore moreSamsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
What are Biologics and Biosimilars?
As Teva’s Vice President of Biologics, it's Nir Shapir’s job to oversee the creation of biopharmaceuticals, ensuring this complicated process works like a finely tuned orchestra. Go behind the scenes in our laboratory to find out how these medicines are made.
Transcript video
What are biopharmaceuticals? They are complex medicines made from living cells and are often produced using cutting-edge biotechnological methods. As Teva’s Vice President of Biologics, it is Nir Shapir’s job to oversee this complicated process and ensure it works like a finely tuned orchestra. Go behind the scenes in our laboratory to find out more.
Join us on a journey that charts where biopharmaceuticals came from and where they may be going.